12:00 AM
Aug 22, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AC5 Surgical Hemostatic Device: Clinical trial data

Top-line data from a single-blind, Irish clinical trial in 46 patients with bleeding wounds due to >=2 skin lesion excisions showed that topical AC5 administered by the AC5 Surgical Hemostatic Device met the primary endpoint of safety up to 30 days...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >